title: Growth in disorders of adrenal hyperfunction.
abstract: Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 +/- 0.42 and 1.3 +/- 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m(2)/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4-17.8 years, with Cushing's disease (CD). At diagnosis, mean height SDS was -1.81 (1.2 to -4.17), 53% < -1.8 SDS, height velocity in 6 was 0.9-3.8 cm/year and mean BMI SDS 2.29 (0.7-5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1-108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10-29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 +/- 3.4 years, growth after cure was studied for 9.1 +/- 5.0 years. Nine had no catch-up growth in the interval of 0.3-1.1 years after cure (mean HV 5.3 +/- 2.4 cm/year). All these had GH deficiency peak GH 0.5-20.9 mU/l, and received hGH 2.7 mg/m(2)/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS-target Ht SDS) -1.72 +/- 1.26 improving to -0.83 +/- 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (-2.9 to 3.0), -0.8 (6.0 to 2.2), 0.7 (-7.9 to 9.5) respectively, whereas SHBG was reduced at -2.1 (-5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height.
authors.affiliation: Department of Endocrinology, St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK. m.o.savage@qmul.ac.uk
authors.forename: M O
authors.initials: MO
authors.lastname: Savage
authors.forename: S
authors.initials: S
authors.lastname: Scommegna
authors.forename: P V
authors.initials: PV
authors.lastname: Carroll
authors.forename: J T F
authors.initials: JT
authors.lastname: Ho
authors.forename: J P
authors.initials: JP
authors.lastname: Monson
authors.forename: G M
authors.initials: GM
authors.lastname: Besser
authors.forename: A B
authors.initials: AB
authors.lastname: Grossman
mesh_terms: D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D000312:Adrenal Hyperplasia, Congenital / Q000150:complications; D000308:Adrenocortical Hyperfunction / Q000150:complications*; D000365:Age Determination by Skeleton; D000728:Androgens / Q000097:blood / Q000378:metabolism; D001827:Body Height; D002648:Child; D003480:Cushing Syndrome / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006130:Growth Disorders / Q000209:etiology*; D019382:Human Growth Hormone / Q000172:deficiency; D006801:Humans; D008297:Male
chemical_list: D000728:Androgens; D019382:Human Growth Hormone